본문 바로가기
KERD
논문KCI 등재

Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease

Kotani Kohei|Kawada Norifumi
거트앤리버 소화기연관학회협의회|2024.01|Gut and Liver|제18권 제1호|pp. 27-39|DOI 10.5009/gnl230072

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Hepatitis BElasticity imaging techniquesPortal hypertensionHepatitis CSplanchnic circulation

초록

In chronic liver disease, hepatic stellate cell activation and degeneration of liver sinusoidal endothelial cells lead to structural changes, which are secondary to fibrosis and the presence of regenerative nodules in the sinusoids, and to functional changes, which are related to vasoconstriction. The combination of such changes increases intrahepatic vascular resistance and causes portal hypertension. The subsequent increase in splanchnic and systemic hyperdynamic circulation further increases the portal blood flow, thereby exacerbating portal hypertension. In clinical practice, the hepatic venous pressure gradient is the gold-standard measure of portal hypertension; a value of ≥10 mm Hg is defined as clinically significant portal hypertension, which is severe and is associated with the risk of liver-related events. Hepatic venous pressure gradient measurement is somewhat invasive, so evidence on the utility of risk stratification by elastography and serum biomarkers is needed. The various stages of cirrhosis are associated with different outcomes. In viral hepatitis-related cirrhosis, viral suppression or elimination by nucleos(t)ide analog or direct-acting antivirals results in recompensation of liver function and portal pressure. However, careful follow-up should be continued, because some cases have residual clinically significant portal hypertension even after achieving sustained virologic response. In this study, we reviewed the current and future prospects for portal hypertension.

Abstract

In chronic liver disease, hepatic stellate cell activation and degeneration of liver sinusoidal endothelial cells lead to structural changes, which are secondary to fibrosis and the presence of regenerative nodules in the sinusoids, and to functional changes, which are related to vasoconstriction. The combination of such changes increases intrahepatic vascular resistance and causes portal hypertension. The subsequent increase in splanchnic and systemic hyperdynamic circulation further increases the portal blood flow, thereby exacerbating portal hypertension. In clinical practice, the hepatic venous pressure gradient is the gold-standard measure of portal hypertension; a value of ≥10 mm Hg is defined as clinically significant portal hypertension, which is severe and is associated with the risk of liver-related events. Hepatic venous pressure gradient measurement is somewhat invasive, so evidence on the utility of risk stratification by elastography and serum biomarkers is needed. The various stages of cirrhosis are associated with different outcomes. In viral hepatitis-related cirrhosis, viral suppression or elimination by nucleos(t)ide analog or direct-acting antivirals results in recompensation of liver function and portal pressure. However, careful follow-up should be continued, because some cases have residual clinically significant portal hypertension even after achieving sustained virologic response. In this study, we reviewed the current and future prospects for portal hypertension.

참고문헌 (141)

  1. Khanna R, "Non-cirrhotic portal hypertension : diagnosis and management", J Hepatol, 60, pp.421~441 (2014)
  2. Garcia-Tsao G, "Portal hypertensive bleeding in cirrhosis : risk stratification, diagnosis, and management : 2016 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 65, pp.310~335 (2017)
  3. Ohfuji S, "Japanese periodical nationwide epidemiologic survey of aberrant portal hemodynamics", Hepatol Res, 49, pp.890~901 (2019)
  4. Murai Y, "Prognostic factors in patients with idiopathic portal hypertension : two Japanese nationwide epidemiological surveys in 1999 and 2005", Hepatol Res, 42, pp.1211~1220 (2012)
  5. Sarin SK, "Noncirrhotic portal fibrosis", idiopathic portal hypertension : APASL recommendations for diagnosis and treatment, 2007, pp.1, 398~413
  6. Siramolpiwat S, "Idiopathic portal hypertension : natural history and long-term outcome", Hepatology, 59, pp.2276~2285 (2014)
  7. De Gottardi A, "Porto-sinusoidal vascular disease : proposal and description of a novel entity", Lancet Gastroenterol Hepatol, 4, pp.399~411 (2019)
  8. Chougule A, "Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis", Hepatol Int, 12, pp.158~166 (2018)
  9. Kotani K, "Long-term outcome of pediatric noncirrhotic portal fibrosis from the viewpoint of endoscopic profile", Hepatol Int, 14, pp.164~166 (2020)
  10. Rajesh S, "Non-cirrhotic portal hypertension : an imaging review", Abdom Radiol(NY), 43, pp.1991~2010 (2018)
  11. de Franchis R, "Baveno VII : renewing consensus in portal hypertension", J Hepatol, 76, pp.959~974 (2022)
  12. García-Pagán JC, "Functional aspects on the pathophysiology of portal hypertension in cirrhosis", J Hepatol, 57, pp.458~461 (2012)
  13. Selicean S, "Regression of portal hypertension : underlying mechanisms and therapeutic strategies", Hepatol Int, 15, pp.36~50 (2021)
  14. Iredale JP, "Extracellular matrix degradation in liver fibrosis : biochemistry and regulation", Biochim Biophys Acta, 1832, pp.876~883 (2013)
  15. Rockey DC, "Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture", J Submicrosc Cytol Pathol, 24, pp.193~203 (1992)
  16. Rothermund L, "Regulation of the hepatic endothelin system in advanced biliary fibrosis in rats", Clin Chem Lab Med, 38, pp.507~512 (2000)
  17. Yokomori H, "Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver", Liver, 21, pp.114~122 (2001)
  18. Zhang JX, "Endothelin-1 induces direct constriction of hepatic sinusoids", Am J Physiol, 266(4 Pt 1), pp.G624~G632 (1994)
  19. Tandon P, "Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure : a systematic review and meta-analysis", J Hepatol, 53, pp.273~282 (2010)
  20. Tsochatzis EA, "Liver cirrhosis", Lancet, 383, pp.1749~1761 (2014)
  21. McConnell M, "Biology of portal hypertension", Hepatol Int, 12(Suppl 1), pp.11~23 (2018)
  22. Wisse E, "An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids", J Ultrastruct Res, 31, pp.125~150 (1970)
  23. Fernández M, "Angiogenesis in liver disease", J Hepatol, 50, pp.604~620 (2009)
  24. Bhunchet E, "Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis : a mechanism to maintain liver blood flow", Hepatology, 18, pp.1450~1458 (1993)
  25. Rockey DC, "Reduced nitric oxide production by endothelial cells in cirrhotic rat liver : endothelial dysfunction in portal hypertension", Gastroenterology, 114, pp.344~351 (1998)
  26. Bosch J, "Evolution in the understanding of the pathophysiological basis of portal hypertension : how changes in paradigm are leading to successful new treatments", J Hepatol, 62(1 Suppl), pp.S121~S130 (2015)
  27. Fukui H, "Leaky gut and gut-liver axis in liver cirrhosis : clinical studies update", Gut Liver, 15, pp.666~676 (2021)
  28. Lin RS, "Endotoxemia in patients with chronic liver diseases : relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation", J Hepatol, 22, pp.165~172 (1995)
  29. Casulleras M, "Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure", Cells, 9, pp.2632~ (2020)
  30. Engelmann C, "Pathophysiology of decompensated cirrhosis : portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction", J Hepatol, 75(Suppl 1), pp.S49~S66 (2021)
  31. Sarin SK, "Acute-on-chronic liver failure : consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)2014", Hepatol Int, 8, pp.453~471 (2014)
  32. Moreau R, "Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis", Gastroenterology, 144, pp.1426~1437 (2013)
  33. Trebicka J, "The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology", J Hepatol, 73, pp.842~854 (2020)
  34. Sikuler E, "Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model", Am J Physiol, 248(6 Pt 1), pp.G618~G625 (1985)
  35. Abraldes JG, "Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state", Am J Physiol Gastrointest Liver Physiol, 290, pp.G980~G987 (2006)
  36. Alukal JJ, "Hyponatremia in cirrhosis : an update", Am J Gastroenterol, 115, pp.1775~1785 (2020)
  37. Martin PY, "Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis", N Engl J Med, 339, pp.533~541 (1998)
  38. Grace JA, "Activation of the MAS receptor by angiotensin-(1-7)in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis", Gastroenterology, 145, pp.874~884 (2013)
  39. Fernandez M, "Molecular pathophysiology of portal hypertension", Hepatology, 61, pp.1406~1415 (2015)
  40. Iwakiri Y, "The hyperdynamic circulation of chronic liver diseases : from the patient to the molecule", Hepatology, 43(2 Suppl 1), pp.S121~S131 (2006)
  41. Møller S, "The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis", Liver Int, 38, pp.570~580 (2018)
  42. Bolognesi M, "Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis", World J Gastroenterol, 20, pp.2555~2563 (2014)
  43. Rosenberg WM, "Serum markers detect the presence of liver fibrosis : a cohort study", Gastroenterology, 127, pp.1704~1713 (2004)
  44. Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease : validating the European Liver Fibrosis Panel and exploring simple markers", Hepatology, 47, pp.455~460 (2008)
  45. Fontana RJ, "Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C", Hepatology, 47, pp.789~798 (2008)
  46. Daniels SJ, "ADAPT : an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis", Hepatology, 69, pp.1075~1086 (2019)
  47. Murawaki Y, "Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease : relationship to liver histology", Hepatology, 20(4 Pt 1), pp.780~787 (1994)
  48. Yoneda M, "Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage", J Gastroenterol, 42, pp.375~381 (2007)
  49. Yamasaki K, "Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients", Hepatology, 60, pp.1563~1570 (2014)
  50. Nakagawa H, "Autotaxin as a novel serum marker of liver fibrosis", Clin Chim Acta, 412, pp.1201~1206 (2011)
  51. Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and Fibrotest", Hepatology, 46, pp.32~36 (2007)
  52. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
  53. Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD : a systematic review and meta-analysis", J Hepatol, 73, pp.252~262 (2020)
  54. Parkes J, "Enhanced Liver Fibrosis(ELF)test accurately identifies liver fibrosis in patients with chronic hepatitis C", J Viral Hepat, 18, pp.23~31 (2011)
  55. Lok AS, "Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests : results of the HALT-C cohort", Hepatology, 42, pp.282~292 (2005)
  56. Castera L, "Non invasive evaluation of portal hypertension using transient elastography", J Hepatol, 56, pp.696~703 (2012)
  57. Bosch J, "The clinical use of HVPG measurements in chronic liver disease", Nat Rev Gastroenterol Hepatol, 6, pp.573~582 (2009)
  58. Casu S, "A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures", Liver Int, 35, pp.695~703 (2015)
  59. Yamamoto A, "Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein", Gut, 70, pp.1199~1201 (2021)
  60. de Franchis R, "Expanding consensus in portal hypertension : report of the Baveno VI Consensus Workshop : stratifying risk and individualizing care for portal hypertension", J Hepatol, 63, pp.743~752 (2015)
  61. Abraldes JG, "Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis : the"Anticipate"study", Hepatology, 64, pp.2173~2184 (2016)
  62. Pons M, "Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease", Am J Gastroenterol, 116, pp.723~732 (2021)
  63. Dajti E, "A combined Baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease", Am J Gastroenterol, 117, pp.1825~1833 (2022)
  64. Reiberger T, "The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis", Hepatol Commun, 6, pp.950~964 (2022)
  65. Fierbinteanu-Braticevici C, "Spleen stiffness as predictor of esophageal varices in cirrhosis of different etiologies", Sci Rep, 9, pp.16190~ (2019)
  66. Mejias M, "Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension", J Hepatol, 52, pp.529~539 (2010)
  67. Chen SH, "Noninvasive assessment of liver fibrosis via spleen stiffness measurement using acoustic radiation force impulse sonoelastography in patients with chronic hepatitis B or C", J Viral Hepat, 19, pp.654~663 (2012)
  68. Buechter M, "Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation", Dig Liver Dis, 50, pp.54~60 (2018)
  69. Colecchia A, "Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis", Gastroenterology, 143, pp.646~654 (2012)
  70. Takuma Y, "Prediction of oesophageal variceal bleeding by measuring spleen stiffness in patients with liver cirrhosis", Gut, 65, pp.354~355 (2016)
  71. Marasco G, "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection", J Hepatol, 70, pp.440~448 (2019)
  72. Stefanescu H, "A novel spleendedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices", Liver Int, 40, pp.175~185 (2020)
  73. Marasco G, "Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients", Hepatol Int, 14, pp.850~857 (2020)
  74. Colecchia A, "A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease", J Hepatol, 69, pp.308~317 (2018)
  75. Stefanescu H, "Liver stiffness assessed by ultrasound shear wave elastography from general electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease", Ultraschall Med, 41, pp.526~533 (2020)
  76. Dajti E, "The role of liver and spleen elastography in advanced chronic liver disease", Minerva Gastroenterol(Torino), 67, pp.151~163 (2021)
  77. Talwalkar JA, "Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension", AJR Am J Roentgenol, 193, pp.122~127 (2009)
  78. Nedredal GI, "Portal hypertension correlates with splenic stiffness as measured with MR elastography", J Magn Reson Imaging, 34, pp.79~87 (2011)
  79. Huang SY, "Evaluation of liver fibrosis and hepatic venous pressure gradient with MR elastography in a novel swine model of cirrhosis", J Magn Reson Imaging, 39, pp.590~597 (2014)
  80. Ronot M, "Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis", Eur Radiol, 24, pp.1394~1402 (2014)
  81. Huwart L, "Magnetic resonance elastography for the noninvasive staging of liver fibrosis", Gastroenterology, 135, pp.32~40 (2008)
  82. Ichikawa S, "Comparison of the diagnostic accuracies of magnetic resonance elastography and transient elastography for hepatic fibrosis", Magn Reson Imaging, 33, pp.26~30 (2015)
  83. Horowitz JM, "Evaluation of hepatic fibrosis : a review from the society of abdominal radiology disease focus panel", Abdom Radiol(NY), 42, pp.2037~2053 (2017)
  84. Abe H, "Clinical application of magnetic resonance elastography in chronic liver disease", Hepatol Res, 48, pp.780~787 (2018)
  85. Matsui N, "Magnetic resonance elastography increases usefulness and safety of non-invasive screening for esophageal varices", J Gastroenterol Hepatol, 33, pp.2022~2028 (2018)
  86. Kennedy P, "MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension", Eur Radiol, 32, pp.8339~8349 (2022)
  87. Danielsen KV, "Using MR elastography to assess portal hypertension and response to betablockers in patients with cirrhosis", Liver Int, 41, pp.2149~2158 (2021)
  88. Shi Y, "Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C", Radiology, 301, pp.154~162 (2021)
  89. Ajmera V, "Liver stiffness on magnetic resonance elastography and the MEFIB index and liverrelated outcomes in nonalcoholic fatty liver disease : a systematic review and meta-analysis of individual participants", Gastroenterology, 163, pp.1079~1089 (2022)
  90. Qi X, "Virtual hepatic venous pressure gradient with CT angiography(CHESS 1601) : a prospective multicenter study for the noninvasive diagnosis of portal hypertension", Radiology, 290, pp.370~377 (2019)
  91. Furuichi Y, "Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography", J Gastroenterol, 48, pp.1061~1068 (2013)
  92. Attia D, "Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension", Ultraschall Med, 36, pp.603~610 (2015)
  93. Matsui T, "Usefulness of virtual touch tissue quantification for predicting the presence of esophageal varices in patients with liver cirrhosis", JGH Open, 5, pp.695~704 (2021)
  94. Kotani K, "Per-rectal portal scintigraphy as an alternative measure of hepatic venous pressure gradient in chronic liver disease : a preliminary report", Clin Physiol Funct Imaging, 41, pp.334~341 (2021)
  95. Okamura H, "A noninvasive diagnostic approach using per-rectal portal scintigraphy for sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation", Bone Marrow Transplant, 55, pp.470~472 (2020)
  96. Hai Y, "Network metaanalysis : noninvasive imaging modalities for identifying clinically significant portal hypertension", Dig Dis Sci, 67, pp.3313~3326 (2022)
  97. Hu X, "Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease : a systematic review and meta-analysis", Eur Radiol, 31, pp.2392~2404 (2021)
  98. Singh R, "Accuracy of liver and spleen stiffness on magnetic resonance elastography for detecting portal hypertension : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 32, pp.237~245 (2021)
  99. Liu F, "Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis(CHESS1701) : a prospective multicenter study", EBioMedicine, 36, pp.151~158 (2018)
  100. Tseng Y, "Application of CT-based radiomics in predicting portal pressure and patient outcome in portal hypertension", Eur J Radiol, 126, pp.108927~ (2020)
  101. Park HJ, "Radiomics and deep learning : hepatic applications", Korean J Radiol, 21, pp.387~401 (2020)
  102. Marozas M, "Noninvasive evaluation of portal hypertension using a supervised learning technique", J Healthc Eng, 2017, pp.6183714~ (2017)
  103. Liu Y, "Deep convolutional neural network-aided detection of portal hypertension in patients with cirrhosis", Clin Gastroenterol Hepatol, 18, pp.2998~3007 (2020)
  104. Bosch J, "A machine learning approach to liver histological evaluation predicts clinically significant portal hypertension in NASH cirrhosis", Hepatology, 74, pp.3146~3160 (2021)
  105. Ahn JC, "Application of artificial intelligence for the diagnosis and treatment of liver diseases", Hepatology, 73, pp.2546~2563 (2021)
  106. Manolakopoulos S, "Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension", J Hepatol, 51, pp.468~474 (2009)
  107. Wang Q, "Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis", J Hepatol, 77, pp.1564~1572 (2022)
  108. Farina E, "Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years", Aliment Pharmacol Ther, 57, pp.1407~1416 (2023)
  109. Lee HW, "Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B", Clin Gastroenterol Hepatol, 19, pp.1950~1958 (2021)
  110. Jachs M, "Long-term outcome of HBVinfected patients with clinically significant portal hypertension achieving viral suppression", J Pers Med, 12, pp.239~ (2022)
  111. Lampertico P, "The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study", J Hepatol, 63, pp.1118~1125 (2015)
  112. Yang HI, "Hepatitis B e antigen and the risk of hepatocellular carcinoma", N Engl J Med, 347, pp.168~174 (2002)
  113. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  114. Tada T, "HBcrAg predicts hepatocellular carcinoma development : an analysis using timedependent receiver operating characteristics", J Hepatol, 65, pp.48~56 (2016)
  115. Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
  116. Marzano A, "Liver stiffness-based model for portal hypertension and hepatocellular cancer risk in HBV responsive to antivirals", Minerva Gastroenterol Dietol, 65, pp.11~19 (2019)
  117. Papatheodoridis GV, "Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B", J Hepatol, 72, pp.1088~1096 (2020)
  118. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
  119. Mizokami M, "Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial", Lancet Infect Dis, 15, pp.645~653 (2015)
  120. Forns X, "Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis(EXPEDITION-1) : a single-arm, open-label, multicentre phase 3 trial", Lancet Infect Dis, 17, pp.1062~1068 (2017)
  121. Kwo PY, "Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis", J Hepatol, 67, pp.263~271 (2017)
  122. Tamori A, "Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world", Hepatol Res, 49, pp.1365~1373 (2019)
  123. Tahata Y, "Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis : a Japanese real-world multicenter study", J Gastroenterol, 56, pp.67~77 (2021)
  124. El-Sherif O, "Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection", Gastroenterology, 154, pp.2111~2121 (2018)
  125. Tada T, "Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1-and 2-infected patients with decompensated cirrhosis : a nationwide multicenter study by the Japanese Red Cross Liver Study Group", J Med Virol, 93, pp.6247~6256 (2021)
  126. Díez C, "Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis", Clin Infect Dis, 71, pp.2726~2729 (2020)
  127. Afdhal N, "Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension", J Viral Hepat, 24, pp.823~831 (2017)
  128. Mandorfer M, "Sustained virologic response to interferon-free therapies ameliorates HCVinduced portal hypertension", J Hepatol, 65, pp.692~699 (2016)
  129. Lens S, "Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis", Gastroenterology, 153, pp.1273~1283 (2017)
  130. Lens S, "Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension", J Hepatol, 73, pp.1415~1424 (2020)
  131. Semmler G, "Non-invasive tests for clinically significant portal hypertension after HCV cure", J Hepatol, 77, pp.1573~1585 (2022)
  132. Kotani K, "Shortterm hepatocyte function and portal hypertension outcomes of sofosbuvir", velpatasvir for decompensated hepatitis Crelated cirrhosis, 2023, pp.58, 394~404
  133. Ahn YH, "Independent risk factors for hepatocellular carcinoma recurrence after direct-acting antiviral therapy in patients with chronic hepatitis C", Gut Liver, 15, pp.410~419 (2021)
  134. Hutchinson SJ, "Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis : a national record-linkage study", Gut, 69, pp.2223~2231 (2020)
  135. D'Ambrosio R, "Incidence of liver-and non-liver-related outcomes in patients with HCVcirrhosis after SVR", J Hepatol, 76, pp.302~310 (2022)
  136. Tahata Y, "Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis", J Gastroenterol, 57, pp.120~132 (2022)
  137. Kozuka R, "Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort", J Viral Hepat, 30, pp.374~385 (2023)
  138. Verna EC, "DAA therapy and long-term hepatic function in advanced", decompensated cirrhosis : real-world experience from HCV-TARGET cohort, 2020, pp.73, 540~548
  139. Nagaoki Y, "Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients", Hepatol Res, 50, pp.1222~1233 (2020)
  140. Lens S, "Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy", Clin Gastroenterol Hepatol, 13, pp.1846~1853 (2015)
  141. Sanduzzi-Zamparelli M, "Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules", J Hepatol, 76, pp.874~882 (2022)

이 간행물의 다른 논문 (22건)

Delayed Perforation after Gastric Endoscopic Submucosal Dissection: Proceed to Prompt Intervention If AcceptableAbe Seiichiropp. 1-2The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular CarcinomaKim Beom Kyungpp. 3-4Investigating Alternative Treatment Options Unfeasible for Local Ablation Therapy in Patients with Small Solitary Hepatocellular Carcinomas김인희, 이창훈pp. 5-6Non-Contrast Abbreviated Magnetic Resonance Imaging: A Cost-Effective Rookie in Hepatocellular Carcinoma Surveillance for Cirrhotic PatientsHeo Subin, Choi Won-Mookpp. 7-9Clinical Practice Guideline for Percutaneous Endoscopic GastrostomyGong Eun Jeong, Park Chan Hyuk, Lee Moon Sung, 임철현, 김상훈, 이주엽, Choi Miyoung, 심기남, Byeon Jeong-Sik, 송근암, Shin Cheol Min, Lim Hyun, Joo Moon Kyung, Choi Hyuk Soon, Lee Oh Young, Park Jong-Jae, 태정현pp. 10-26
원문 보기